BRCA 1 AND BRCA 2 Gene Mutations and Increased Risk Of Breast Cancer Abstract References Research Proposal Obed K. Agyei and Natalie A. Rich Department.

Slides:



Advertisements
Similar presentations
Cancer and Cell Biology. Cancer Facts Group of 100 diseases that develop across time Characterized by uncontrolled cell division Can develop in virtually.
Advertisements

Breast Cancer An Overview Dr. Christina Tzagarakis-Foster November 9, 2006.
Tumor Markers Lecture one By Dr. Reem Sallam. Objectives  To briefly introduce cancers, their incidence, some common terms, and staging system.  To.
Breast MR Imaging Workshop th September 2014 High-Risk Screening Evidence-based Clinical Indications for Breast MRI Dr. Muhamad Zabidi Ahmad, AMDI.
Carolina Breast Cancer Study: Breast cancer subtypes and race Robert Millikan University of North Carolina Chapel Hill, NC.
Copyright © 2003 Pearson Education, Inc. publishing as Benjamin Cummings. MICHAEL D. JOHNSON CANCER: UNCONTROLLED CELL DIVISION AND DIFFERENTIATION CHAPTER.
Investigating the BRCA1 Mutation F.R.E.S.H Docs. Angelina Jolie Actress, Film director, and Screenwriter Mother had Breast Cancer and died at 56 from.
Estimating the penetrances of breast and ovarian cancer in the carriers of BRCA1/2 mutations Silvano Presciuttini University of Pisa, Italy.
Type Of Cancer:Location: CarcinomaEpithelial Cells SarcomaConnective Tissue LeukemiaCirculatory / Lymphatic.
Endometriosis and Cancer…Is there a Causal Link? Paula Payton Masters Project 2/22/06 Advisor: Prof Eileen VanDyke.
What Can BRCA Mutations Tell Us About Ancestry? Krizia Gupiteo, Anthropology CONCLUSIONS OBJECTIVES/RESEARCH QUESTIONS RESULTS BACKGROUND IMPLICATIONS.
Tumor Markers Lecture one By Dr. Waheed Al-Harizi.
Introduction of Cancer Molecular Epidemiology Zuo-Feng Zhang, MD, PhD University of California Los Angeles.
BRCA1 The First Breast Cancer Gene Presentation By Liz Mosley.
Physical Activity and Reduction of Breast Cancer Risk.
Breast Cancer 101 Barbara Lee Bass, MD, FACS Professor of Surgery
Breast Cancer By Kajal Haghmoradi.
22/10/1436. Addar Professor Gyneoncologist OB/GYN Dept. KKUH and College of Medicine MKing Saud University.
Understanding and Optimizing Treatment of Triple Negative Breast Cancer Edith Peterson Mitchell, MD, FACP Clinical Professor of Medicine and Medical Oncology.
Genetic and Molecular Epidemiology
BRCA1/2 Mutation Testing and Breast/Ovarian Cancer in the Ashkenazi Jewish Population Glenn E Palomaki, B.S. Foundation for Blood Research Scarborough,
Breast Cancer Risk Factors
The Cancer Pedigree BRCA What?. Outline Introduction: Understanding the weight of genetics in Ovarian Breast Cancer BRCA 1 and BRCA 2 Genes – Function.
METHODS This project is an evidence based literature review conducted using the databases of Medline, AbstractsFirst, and Cochrane. The search terms used.
Genetic Alterations of TP53 Gene in Brain Astrocytic Tumours Methodology Θ Eighty-three brain tumor biopsies were collected and used in this study. Thirty.
Menopause: The Journal of The North American Menopause Society
SC430 Molecular Cell Biology
Atoosa Adibi MD. Department of Radiology Isfahan University Of Medical Sciences.
Cancer Estimated US Cancer Cases Cancer Incidence Rates for Women, USA.
Angelina Jolie The White Coat Wonder. Rational  The purpose of our research is to enrich the Premed-A community with the knowledge of other cancers caused.
Breast Cancer. What is this Disease? Second leading cause of cancer death in women Malignant (cancerous) tumor –Develops from cells in the breast that.
INCIDENCE AND SURVIVAL TRENDS OF COLORECTAL CANCER FROM 2002 TO 2011 BE Ansa; E Alema-Mensah; MD Claridy; JQ Sheats; B Fontenot, and SA Smith Georgia Regents.
Cancer Healthy Kansans 2010 Steering Committee Meeting May 12, 2005.
 Cancer is a group of more than 100 diseases that develop over time › Involve the uncontrolled division of the body’s cells  Cancer is the 2 nd leading.
Imaging examinations of breasts
Insert Program or Hospital Logo Introduction Melanoma is notoriously resistant to chemotherapy. While surgical resection and adjuvant chemotherapy can.
Metabolic Syndrome and Recurrence within the 21-Gene Recurrence Score Assay Risk Categories in Lymph Node Negative Breast Cancer Lakhani A et al. Proc.
“The African American Prostate Cancer Crisis in Numbers”
Breast Cancer Breast Cancer DR/FATMA AL-THOUBAITY ASSOCIATE PROFESSOR SURGICAL CONSULTANT.
Breast Cancer By: Christen Scott.
Breast Cancer. Introduction  As old as 1600 BC  Emerges from inner lining of milk ducts  Or the lobules that supply milk  Types:  DCIS  LCIS.
 Among all cancers, breast cancer has been the 2 nd leading cause of death in women (right behind lung cancer)  Causes about 40,000 deaths annually.
Personal Risk Factors Gender being a woman is the main risk factor for developing breast cancer (100 times more common in women) Age occurrence increase.
Incorporating Multiple Evidence Sources for the Assessment of Breast Cancer Policies and Practices J. Jackson-Thompson, Gentry White, Missouri Cancer Registry,
Understanding Cancer and Related Topics
What is cancer? Mitosis- normal cell division Cancer- uncontrolled cell division (carcinoma) –Develops into a tumor Benign- does not spread –(Not Cancerous)
Breast Cancer. Breast cancer is a disease in which malignant cells form in the tissues of the breast – “National Breast Cancer Foundation” The American.
Javad Jamshidi Fasa University of Medical Sciences, December 2015 Cancer Genetics Session 4 Medical Genetics.
Pathology.
Breast cancer affects 1 in 8 women during their lives. 1 Population Statistics.
Regulating the Cell Cycle the cell cycle has a built-in genetic signals to tell cells when to start and stop dividing –proto-onco genes – genes that encourage.
Cancer 101: A Cancer Education and Training Program for [Target Population] Date Location Presented by: Presenter 1 Presenter 2.
Bladder cancer! By Shamier Daniels. it is a disease in which abnormal cells multiply...
Breast Cancer »Breast cancer is a malignant tumor that starts in the cells of the breast. »The disease occurs almost entirely in women,but men can get.
CELL DIVISION GOING WRONG: Cancer When cells grow and divide out of control, they cause a group of diseases called cancer.cancer The result is a change.
Breast Cancer 1. Leukemia & Lymphoma New diagnoses each year in the US: 112, 610 Adults 5,720 Children 43,340 died of leukemia or lymphoma in
By: Anthony, Sophia, Jessica, Terrance, and Sierra.
Cell Biology & Cancer Unit Objective 1 Cancer types, incidence, pre-disposition, and risk factors Biomedical Technology.
The Elliott Breast Center * Baton Rouge, LA *
Karyotyping Cancer.
Nurdianah HF, Nizuwan A, Muhamad Yusri M
Jeopardy Testing 1, 2, 3 She Has The Cancer Radiation or Chemo?
Uncontrolled Cell Division and Differentiation
Cell Biology and Cancer Unit H.
breast cancer 2, early onset What does this protein make up or do?
Breast Cancer.
Specific Tumor Suppressor Genes
Presentation transcript:

BRCA 1 AND BRCA 2 Gene Mutations and Increased Risk Of Breast Cancer Abstract References Research Proposal Obed K. Agyei and Natalie A. Rich Department of Biology, North Carolina State University Conclusion Barnes R, Masood S, Barker E, Rosengard AM, Coggin DL, Crowell T, King CR, Porter-Jordan K, Wargotz ES, Liotta LA. Low nm23 protein expression in infiltrating ductal breast carcinomas correlates with reduced patient survival. Am J Pathol 1991 Aug;139(2): Hofmann, W., and P M. Schlag. "BRCA1 and BRCA2 - Breast Cancer Susceptibility Genes." J Cancer Res Clin Oncol (2000): Web. 4 Mar "Cancer Risks in BRCA2 Mutation Carriers." Journal of National Cancer Institute (1999): Web. 4 Mar Image courtesy of prweb.com Center for Disease Control and Prevention. “Breast Cancer Statistics.” (accessed March, 2011). Kretschmer C, Sterner-Kock A, Siedentopf F, Schoenegg W, Schlag PM, Kemmner W. Identification of early molecular markers for breast cancer. Mol Cancer 2011 Feb 11;10(1):15. Smith, Margaret., Susan Fawcett, Emanouil Sigalas, Richard Bell, Sophie Devery, Nikolina Andrieska, and Ingrid Winship. "Familial Breast Cancer: Double Heterozygosity for BRCA1 and BRCA2 Mutations with Differing Phenotypes." Familial Cancer (2008): Web. 3 Mar Veltman, J., R Mann, and T Kok. "Breast Tumor Characteristics of BRCA1 and BRCA2 Gene Mutation Carriers on MRI." Eur Radiol (2008): Web. 4 Mar American Cancer Society. “Breast Cancer Overview.” (accessed March 5, 2011). Hall, Michael J., Julia E. Reid, and Lynn A. Burbidge. "BRCA1 and BRCA2 Mutations in Women of Different Ethnicities Undergoing Testing for Hereditary Breast-ovarian Cancer." Cancer (2009): Web. 4 Mar Breast Cancer affects nearly 273,000 people every year in the United States, and women account for almost 95% of the individuals affected. Private companies and the U.S. government spend almost $1 billion on breast cancer research annually to improve its diagnosis and treatment. Breast cancer is a complex, deadly disease highly associated with genetic abnormalities. Since there are numerous types and sub-types of breast cancer, it is very difficult to understand the basic cause of the disease. The objective of this paper is to review how genetic abnormalities correlate with different types of breast cancer. Research in this field has led scientists to determine the main types of breast cancer that manifest in humans and the genetic causes that lead to these manifestations. Much of the research in this field involves experimentation with genes. BRCA1/2 genes were examined among patients with breast cancer and those without the disease. DNA analysis of BRCA1/2 genes was performed. Majority of the patients had mutations on the BRCA1/2 genes while the other control group showed no sign of genetic mutations. Mutations of the BRCA1/2 genes are typically hereditary, but other factors such as radiation can trigger mutations. Types of breast cancer are associated with the part of the breast whose cells are being transformed due to mutated genes, either being the ducts, lobules etc. Further elucidation of the affects of mutated BRCA1/2 is essential for understanding human breast cancer manifestations and future treatment of this complex disease. As seen in Figure 1 and 2, breast cancer incidence rate is higher in Caucasians women but however, more African-American women tend to die from breast cancer than any other ethnic group. This disturbing findings cautioned us to design an experiment that was geared toward examining the cause of this high mortality rate. Goal 1: to determine the rate of BRCA1 and BRCA 2 gene mutations based on a patient’s ethnicity and age. Goal 2: Use Needle Breast Tissue Biopsy to extract cancerous tissues from a total of breast cancer patients. Cells from six healthy patients will also be collected. Goal 3: Use siRNA gene slicing technology to temporary knockdown each of the BRCA genes from the T47D cell lines to determine its effect on mutation rates. Goal 4: Consult a geneticist to assist in the permanent removal of both the BRCA 1 and BRCA 2 genes from the breast cancer cell lines. We expect to find a decrease in mutation rate when BRCA genes are permanently deactivated. A deactivated BRCA gene will prevent all necessary mutations in the TD47 cancer cell lines. We expect to find significant differences in BRCA 1 and BRCA 2 mutation rate among African American and Caucasian women. General Goal Statement Mutations of the BRCA 1&2 tumor suppressor genes have a tremendous effect of the type of breast cancer that an individual can develop, depending on the cell tissues where the BRCA 1&2 genes are being mutated. Studies have shown that mutations in certain genes can lead a person to be more susceptible to developing breast cancer. The most commonly studied genes are the BRCA1 and BRCA2 genes. BRCA 1 and BRCA 2 are human tumor suppressor genes that produces proteins to prevent uncontrollable cell growth. In the absence of BRCA genes, the human body risk the chance of preventing mass cell division. The purpose of this study is to review the risk of BRCA mutations, in comparison to other factors such as protein levels, diet, health, and weight that may contribute to the cause or prevention of breast cancer and the type of breast cancer associated. Introduction Materials and Methods Figure 1 represent the survival rate of patients with low and high nm-23 proteins.(Barnes et al 1991). Figure 2 illustrates breast cancer risk in women. Gray column show risk in women with a strong family history of breast cancer estimated by Easton et.al. (1995); Gray stripped column shows risk in women carrying BRCA 1 or BRCA 2 gene mutation estimated by Struewing et al.(1997); White column shows risk in general population. (Hofmann et al 2000). *Black *White *(Center for Disease Control and Prevention, 2011). Rates per 100,000 persons among 19 age groups. Figure 4. Shows female breast cancer mortality rates in the U.S with respect to ethnicity. (CDC) Results Infiltrating ductal carcinomas with low nm-23 protein had a low rate of survival. Human Ductal Carcinoma In-Situ genes express markers similar to invasive ductal carcinomas in mice. Invasive ductal carcinomas and medullary carcinomas are positive for Cytokeratin 5 and 6 proteins Infiltrating Lobular Carcinoma is positive for 92.7% of estrogen and has a higher presence of p53 tumor suppressor gene Examination of Inflammatory breast cancer tissues showed that the genes had recurrent amplifications than the genes in non-inflammatory breast cancer tissues BRCA1/2 mutations are commonly found in breast cancer patients. Mutations in the BRCA1/2 genes are found in people with a family history of breast cancer. BRCA1/2 gene mutations increase the rate of tumor growth in patients with breast cancer. BRCA1/2 genes increase the risk of a person developing breast cancer by 85%. Majority of BRCA ½ gene mutations are found in ancestral groups The amount of protein levels and gene mutations can determine a patient’s rick of developing breast cancer and chances of survival. As it can be inferred from Figure 1, low levels of nm-23 (a specific type of protein) can reduce the survival rate of infiltrating ductal carcinoma. These findings by Barnes were supported by three pathologists who had similar conclusions. They concluded that high levels of nm-23 protein will increase a patient’s survival of infiltrating ductal carcinoma. Since infiltrating ductal carcinoma is the most common type of all breast cancer, this research is very significant because a progress can be made to reduce its popularity. Few steps that could be taken to reduce the popularity of infiltrating ductal carcinoma include developing medicines that have high concentrations of nm-23 protein. In comparison to BRCA genes, similar conclusions could be drawn because a mutation in BRCA 1 or BRCA 2 gene, as seen in Figure 2, will reduce the production of protein by the BRCA genes. A reduction in protein production cannot prevent cells from stopping its mass division which ultimately ends up in the build up of tumors. In conclusion, BRCA 1 / 2 genes are highly associated with an individual’s risk of developing breast cancer. Mutation of these genes reduces cell signaling during cell division, thus increasing uncontrollable cell division in the body. Acknowledgements This work was supported by the College of Agriculture and Life Sciences, Department of Biology at North Carolina State University, Dr. Miriam Ferzli and Elizabeth Overman. Gene Expression Profiling: [To accurately determine the state of cancerous tumors.] A set of human DCIS and invasive mammary tumors were analyzed using gene expression profiling. Gene Expression of TP53 genes were examined in normal breast epithelial cells and mutated breast epithelial cells. A test was conducted on somatic cells affected by cancerous genes to identify their phenotypes. DNA analysis of the BRCA1 and BRCA2 genes was performed over the course of ten years on women from various ethnic groups. A genetic test was conducted in mice with one or more mutated genes. DNA and RNA were extracted from frozen samples of invasive carcinoma tissues and analyzed for genomic expressions. Population Study Families with the BRCA1 and BRCA2 mutations were investigated to determine the risks of developing breast cancer A database of patients with early stages of breast cancer were studied to determine the status of the TP53 tumor suppressor gene. A nationwide study was conducted to help determine non-genetic factors for developing breast cancer in premenopausal and postmenopausal women. Protein Level Analysis Infiltrating ductal carcinoma were collected from the University of Jacksonville to be accessed for protein staining patterns. Medullary carcinomas of the breast were obtained and examined for the presence of cytokeratin Figure 3. A representation of female breast cancer incidence rates in the U.S with respect to ethnicity. (CDC) High level of nm23 Low level of nm23